Novo Nordisk A/S $NVO Shares Sold by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 11.5% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 170,939 shares of the company’s stock after selling 22,224 shares during the period. Beacon Investment Advisory Services Inc.’s holdings in Novo Nordisk A/S were worth $9,485,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. Lockheed Martin Investment Management Co. increased its stake in shares of Novo Nordisk A/S by 179.4% in the second quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock worth $2,999,000 after acquiring an additional 27,900 shares during the period. Martin Capital Partners LLC increased its stake in shares of Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after purchasing an additional 41,129 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Novo Nordisk A/S by 15,919.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock worth $72,523,000 after purchasing an additional 1,038,137 shares during the period. Unified Investment Management acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at $692,000. Finally, Guild Investment Management Inc. lifted its stake in Novo Nordisk A/S by 20.7% in the 2nd quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock valued at $2,553,000 after buying an additional 6,345 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on NVO shares. HSBC reissued a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Tuesday. Hsbc Global Res cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Morgan Stanley reiterated an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Finally, Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $52.29 on Friday. The stock’s 50-day moving average is $49.35 and its two-hundred day moving average is $56.93. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The firm has a market cap of $233.49 billion, a price-to-earnings ratio of 15.20 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.